nach oben

Heart Failure Reviews

Erschienen in:

14.07.2021

Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments

verfasst von: Nicoletta Orphanou, Efstathios Papatheodorou, Aris Anastasakis

Erschienen in: Heart Failure Reviews | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Dilated cardiomyopathy (DCM) is an umbrella term entailing a wide variety of genetic and non-genetic etiologies, leading to left ventricular systolic dysfunction and dilatation, not explained by abnormal loading conditions or coronary artery disease. The clinical presentation can vary from asymptomatic to heart failure symptoms or sudden cardiac death (SCD) even in previously asymptomatic individuals. In the last 2 decades, there has been striking progress in the understanding of the complex genetic basis of DCM, with the discovery of additional genes and genotype–phenotype correlation studies. Rigorous clinical work-up of DCM patients, meticulous family screening, and the implementation of advanced imaging techniques pave the way for a more efficient and earlier diagnosis as well as more precise indications for implantable cardioverter defibrillator implantation and prevention of SCD. In the era of precision medicine, genotype-directed therapies have started to emerge. In this review, we focus on updates of the genetic background of DCM, characteristic phenotypes caused by recently described pathogenic variants, specific indications for prevention of SCD in those individuals and genotype-directed treatments under development. Finally, the latest developments in distinguishing athletic heart syndrome from subclinical DCM are described.

Elliott P, Andersson B, Arbustini E et al (2007) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial And Pericardial Diseases. Eur Heart J 29(2):270–276. https://doi.org/10.1093/eurheartj/ehm342CrossRefPubMed

Pinto YM, Elliott PM, Arbustini E et al (2016) Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 37(23):1850–1858. https://doi.org/10.1093/eurheartj/ehv727CrossRefPubMed

Anastasakis A, Basso C (2018) “Primary” dilated hearts. Int J Cardiol 257:366–370. https://doi.org/10.1016/j.ijcard.2018.01.002CrossRefPubMed

Henry WL, Gardin JM, Ware JH (1980) Echocardiographic measurements in normal subjects from infancy to old age. Circulation 62(5):1054–1061. https://doi.org/10.1161/01.CIR.62.5.1054CrossRefPubMed

Sinagra G, Elliott PM, Merlo M (2020) Dilated cardiomyopathy: so many cardiomyopathies! Eur Heart J 41(39):3784–3786. https://doi.org/10.1093/eurheartj/ehz908CrossRefPubMed

Maron BJ, Towbin JA, Thiene G et al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807–1816. https://doi.org/10.1161/CIRCULATIONAHA.106.174287CrossRefPubMed

Elliott PM, Anastasakis A, Asimaki A et al (2019) Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail 21(8):955–964. https://doi.org/10.1002/ejhf.1534CrossRefPubMed

Arbustini E, Narula N, Tavazzi L et al (2014) The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol 64(3):304–318. https://doi.org/10.1016/j.jacc.2014.05.027CrossRefPubMed

Arbustini E, Morbini P, Pilotto A, Gavazzi A, Tavazzi L (2000) Genetics of idiopathic dilated cardiomyopathy. Herz 25(3):156–160. https://doi.org/10.1007/s000590050001CrossRefPubMed

10.

Creemers EE, Wilde AA, Pinto YM (2011) Heart failure: advances through genomics. Nat Rev Genet 12(5):357–362. https://doi.org/10.1038/nrg2983CrossRefPubMed

11.

Jacoby D, McKenna WJ (2012) Genetics of inherited cardiomyopathy. Eur Heart J 33(3):296–304. https://doi.org/10.1093/eurheartj/ehr260CrossRefPubMed

12.

Pasotti M, Klersy C, Pilotto A et al (2008) Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 52(15):1250–1260. https://doi.org/10.1016/j.jacc.2008.06.044CrossRefPubMed

13.

van Berlo JH, de Voogt WG, van der Kooi AJ et al (2005) Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med 83(1):79–83. https://doi.org/10.1007/s00109-004-0589-1CrossRefPubMed

14.

van den Berg MP, van Spaendonck-Zwarts KY, van Veldhuisen DJ, Gietema JA, Postma A, van Tintelen JP (2010) Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? Eur J Heart Fail 12(12):1297–1299. https://doi.org/10.1093/eurjhf/hfq175CrossRefPubMed

15.

Rakar S, Sinagra G, Di Lenarda A et al (1997) Epidemiology of dilated cardiomyopathy: a prospective post-mortem study of 5252 necropsies. Eur Heart J 18(1):117–123. https://doi.org/10.1093/oxfordjournals.eurheartj.a015092CrossRefPubMed

16.

Grünig E, Tasman JA, Kücherer H, Franz W, Kübler W, Katus HA (1998) Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 31(1):186–194. https://doi.org/10.1016/S0735-1097(97)00434-8CrossRefPubMed

17.

Bozkurt B, Colvin M, Cook J et al (2016) Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 134(23). https://doi.org/10.1161/CIR.0000000000000455

18.

Mestroni L, Rocco C, Gregori D et al (1999) Familial dilated cardiomyopathy. J Am Coll Cardiol 34(1):181–190. https://doi.org/10.1016/S0735-1097(99)00172-2CrossRefPubMed

19.

Sweet ME, Taylor MR, Mestroni L (2015) Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. Expert Opin Orphan Drugs 3(8):869–876. https://doi.org/10.1517/21678707.2015.1057498CrossRefPubMedPubMedCentral

20.

Hershberger RE, Siegfried JD (2011) Update 2011: Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57(16):1641–1649. https://doi.org/10.1016/j.jacc.2011.01.015CrossRefPubMedPubMedCentral

21.

Dolara A, Cecchi F, Ciaccheri M (1989) Cardiomyopathy in Italy today: extent of the problem. G Ital Cardiol 19(11):1074–1079PubMed

22.

Coughlin SS, Szklo M, Baughman K, Pearson TA (1990) The epidemiology of idiopathic dilated cardiomyopathy in a biracial community. Am J Epidemiol 131(1):48–56. https://doi.org/10.1093/oxfordjournals.aje.a115484CrossRefPubMed

23.

Charron P, Elliott PM, Gimeno JR et al (2018) The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J 39(20):1784–1793. https://doi.org/10.1093/eurheartj/ehx819CrossRefPubMed

24.

Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH (2014) Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63(18):1879–1889. https://doi.org/10.1016/j.jacc.2013.12.021CrossRefPubMed

25.

van Tintelen JP, Hofstra RMW, Katerberg H et al (2007) High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J 154(6):1130–1139. https://doi.org/10.1016/j.ahj.2007.07.038CrossRefPubMed

26.

Anastasakis A, Papatheodorou E, Ritsatos K et al (2018) Sudden unexplained death in the young: epidemiology, aetiology and value of the clinically guided genetic screening. EP Eur 20(3):472–480. https://doi.org/10.1093/europace/euw362CrossRef

27.

Lahrouchi N, Raju H, Lodder EM et al (2020) The yield of postmortem genetic testing in sudden death cases with structural findings at autopsy. Eur J Hum Genet 28(1):17–22. https://doi.org/10.1038/s41431-019-0500-8CrossRefPubMed

28.

Papadakis M, Papatheodorou E, Mellor G et al (2018) The diagnostic yield of Brugada syndrome after sudden death with normal autopsy. J Am Coll Cardiol 71(11):1204–1214. https://doi.org/10.1016/j.jacc.2018.01.031CrossRefPubMed

29.

Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G (2018) Evolving concepts in dilated cardiomyopathy: evolving concepts in DCM. Eur J Heart Fail 20(2):228–239. https://doi.org/10.1002/ejhf.1103CrossRefPubMed

30.

Roberts AM, Ware JS, Herman DS et al (2015) Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med 7(270):270ra6–270ra6. https://doi.org/10.1126/scitranslmed.3010134

31.

Haggerty CM, Damrauer SM, Levin MG et al (2019) Genomics-first evaluation of heart disease associated with titin-truncating variants. Circulation 140(1):42–54. https://doi.org/10.1161/CIRCULATIONAHA.119.039573CrossRefPubMedPubMedCentral

32.

Volkova M, Russell R (2012) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7(4):214–220. https://doi.org/10.2174/157340311799960645CrossRef

33.

George A, Figueredo VM (2011) Alcoholic cardiomyopathy: a review. J Card Fail 17(10):844–849. https://doi.org/10.1016/j.cardfail.2011.05.008CrossRefPubMed

34.

Caforio ALP, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648. https://doi.org/10.1093/eurheartj/eht210CrossRefPubMed

35.

Monda E, Palmiero G, Rubino M et al (2020) Molecular basis of inflammation in the pathogenesis of cardiomyopathies. Int J Mol Sci 21(18):6462. https://doi.org/10.3390/ijms21186462CrossRefPubMedCentral

36.

Kühl U, Pauschinger M, Noutsias M et al (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111(7):887–893. https://doi.org/10.1161/01.CIR.0000155616.07901.35CrossRefPubMed

37.

Caforio ALP, Keeling PJ, McKenna WJ et al (1994) Evidence from family studies for autoimmunity in dilated cardiomyopathy. The Lancet 344(8925):773–777. https://doi.org/10.1016/S0140-6736(94)92339-6CrossRef

38.

Caforio ALP, Mahon NG, Baig MK et al (2007) Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 115(1):76–83. https://doi.org/10.1161/CIRCULATIONAHA.106.641472CrossRefPubMed

39.

Mahon NG, Murphy RT, MacRae CA, Caforio ALP, Elliott PM, McKenna WJ (2005) Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 143(2):108. https://doi.org/10.7326/0003-4819-143-2-200507190-00009CrossRefPubMed

40.

Puntmann VO, Carerj ML, Wieters I et al (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. Published Online 27 Jul 2020 https://doi.org/10.1001/jamacardio.2020.3557

41.

Sandoval Y, Januzzi JL, Jaffe AS (2020) Cardiac troponin for assessment of myocardial injury in COVID-19. J Am Coll Cardiol 76(10):1244–1258. https://doi.org/10.1016/j.jacc.2020.06.068CrossRefPubMedPubMedCentral

42.

Arentz M, Yim E, Klaff L et al (2020) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323(16):1612. https://doi.org/10.1001/jama.2020.4326CrossRefPubMedPubMedCentral

43.

Sliwa K, Hilfiker-Kleiner D, Petrie MC et al (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12(8):767–778. https://doi.org/10.1093/eurjhf/hfq120CrossRefPubMed

44.

Endorsed by the European Society of Gynecology (ESG), the Association for European Paediatric Cardiology (AEPC), and the German Society for Gender Medicine (DGesGM), Authors/Task Force Members, Regitz-Zagrosek V et al (2011) ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32(24):3147–3197. https://doi.org/10.1093/eurheartj/ehr218

45.

Hilfiker-Kleiner D, Haghikia A, Berliner D et al (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 38(35):2671–2679. https://doi.org/10.1093/eurheartj/ehx355CrossRefPubMedPubMedCentral

46.

van Spaendonck-Zwarts KY, van Rijsingen IAW, van den Berg MP et al (2013) Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years’ experience. Eur J Heart Fail 15(6):628–636. https://doi.org/10.1093/eurjhf/hft013CrossRefPubMed

47.

Anastasakis A, Sevdalis E, Papatheodorou E, Stefanadis C (2011) Anderson-Fabry disease: a cardiomyopathy that can be cured. Hell J Cardiol HJC Hell Kardiologike Epitheorese 52(4):316–326

48.

Anastasakis A, Papatheodorou E, Steriotis AK (2013) Fabry disease and cardiovascular involvement. Curr Pharm Des 19(33):5997–6008. https://doi.org/10.2174/13816128113199990353CrossRefPubMed

49.

Michels VV, Moll PP, Miller FA et al (1992) The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 326(2):77–82. https://doi.org/10.1056/NEJM199201093260201CrossRefPubMed

50.

Gigli M, Merlo M, Graw SL et al (2019) Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 74(11):1480–1490. https://doi.org/10.1016/j.jacc.2019.06.072CrossRefPubMedPubMedCentral

51.

Millat G, Bouvagnet P, Chevalier P et al (2011) Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy. Eur J Med Genet 54(6):e570–e575. https://doi.org/10.1016/j.ejmg.2011.07.005CrossRefPubMed

52.

Haas J, Frese KS, Peil B et al (2015) Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 36(18):1123–1135. https://doi.org/10.1093/eurheartj/ehu301CrossRefPubMed

53.

Herman DS, Lam L, Taylor MRG et al (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366(7):619–628. https://doi.org/10.1056/NEJMoa1110186CrossRefPubMedPubMedCentral

54.

Norton N, Li D, Rampersaud E et al (2013) Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet 6(2):144–153. https://doi.org/10.1161/CIRCGENETICS.111.000062CrossRefPubMed

55.

Parks SB, Kushner JD, Nauman D et al (2008) Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 156(1):161–169. https://doi.org/10.1016/j.ahj.2008.01.026CrossRefPubMedPubMedCentral

56.

Taylor MRG, Fain PR, Sinagra G et al (2003) Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 41(5):771–780. https://doi.org/10.1016/s0735-1097(02)02954-6CrossRefPubMed

57.

Kumar S, Baldinger SH, Gandjbakhch E et al (2016) Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol 68(21):2299–2307. https://doi.org/10.1016/j.jacc.2016.08.058CrossRefPubMed

58.

van Rijsingen IAW, Nannenberg EA, Arbustini E et al (2013) Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail 15(4):376–384. https://doi.org/10.1093/eurjhf/hfs191CrossRefPubMed

59.

van Rijsingen IAW, Arbustini E, Elliott PM et al (2012) Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. J Am Coll Cardiol 59(5):493–500. https://doi.org/10.1016/j.jacc.2011.08.078CrossRefPubMed

60.

Priori SG, Blomström-Lundqvist C, Mazzanti A et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with Ventricular Arrhythmias and the prevention of sudden cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316

61.

Hershberger RE, Hedges DJ, Morales A (2013) Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 10(9):531–547. https://doi.org/10.1038/nrcardio.2013.105CrossRefPubMed

62.

Politano L, Nigro V, Nigro G et al (1996) Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 275(17):1335–1338CrossRef

63.

Melacini P, Fanin M, Danieli GA et al (1996) Myocardial involvement is very frequent among patients affected with subclinical Becker’s muscular dystrophy. Circulation 94(12):3168–3175. https://doi.org/10.1161/01.CIR.94.12.3168CrossRefPubMed

64.

Ortiz-Genga MF, Cuenca S, Dal Ferro M et al (2016) Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 68(22):2440–2451. https://doi.org/10.1016/j.jacc.2016.09.927CrossRefPubMed

65.

Brun F, Barnes CV, Sinagra G et al (2014) Titin and desmosomal genes in the natural history of arrhythmogenic right ventricular cardiomyopathy. J Med Genet 51(10):669–676. https://doi.org/10.1136/jmedgenet-2014-102591CrossRefPubMed

66.

Brauch KM, Karst ML, Herron KJ et al (2009) Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 54(10):930–941. https://doi.org/10.1016/j.jacc.2009.05.038CrossRefPubMedPubMedCentral

67.

Norton N, Li D, Rieder MJ et al (2011) Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet 88(3):273–282. https://doi.org/10.1016/j.ajhg.2011.01.016CrossRefPubMedPubMedCentral

68.

Rapezzi C, Arbustini E, Caforio ALP et al (2013) Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(19):1448–1458. https://doi.org/10.1093/eurheartj/ehs397

69.

Charron P, Arad M, Arbustini E et al (2010) Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 31(22):2715–2726. https://doi.org/10.1093/eurheartj/ehq271CrossRefPubMed

70.

Towbin JA, McKenna WJ, Abrams DJ et al (2019) 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 16(11):e301–e372. https://doi.org/10.1016/j.hrthm.2019.05.007CrossRefPubMed

71.

Gulati A, Jabbour A, Ismail TF et al (2013) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309(9):896. https://doi.org/10.1001/jama.2013.1363CrossRefPubMed

72.

Masci PG, Barison A, Aquaro GD et al (2012) Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. Int J Cardiol 157(1):43–47. https://doi.org/10.1016/j.ijcard.2010.11.005CrossRefPubMed

73.

Masci PG, Doulaptsis C, Bertella E et al (2014) Incremental prognostic value of myocardial fibrosis in patients with non–ischemic cardiomyopathy without congestive heart failure. Circ Heart Fail 7(3):448–456. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000996CrossRefPubMed

74.

Shah RV, Januzzi JL (2010) ST2: A novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 7(1):9–14. https://doi.org/10.1007/s11897-010-0005-9CrossRefPubMed

75.

Rehman SU, Mueller T, Januzzi JL (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52(18):1458–1465. https://doi.org/10.1016/j.jacc.2008.07.042CrossRefPubMed

76.

Momiyama Y, Mitamura H, Kimura M (1994) ECG characteristics of dilated cardiomyopathy. J Electrocardiol 27(4):323–328. https://doi.org/10.1016/S0022-0736(05)80270-5CrossRefPubMed

77.

Merlo M, Zaffalon D, Stolfo D et al (2019) ECG in dilated cardiomyopathy: specific findings and long-term prognostic significance. J Cardiovasc Med 20(7):450–458. https://doi.org/10.2459/JCM.0000000000000804CrossRef

78.

Grimm W, Christ M, Bach J, Müller H-H, Maisch B (2003) Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 108(23):2883–2891. https://doi.org/10.1161/01.CIR.0000100721.52503.85CrossRefPubMed

79.

Finocchiaro G, Papadakis M, Dhutia H et al (2019) Electrocardiographic differentiation between ‘benign T-wave inversion’ and arrhythmogenic right ventricular cardiomyopathy. EP Eur 21(2):332–338. https://doi.org/10.1093/europace/euy179CrossRef

80.

Aleksova A, Merlo M, Zecchin M et al (2010) Impact of atrial fibrillation on outcome of patients with idiopathic dilated cardiomyopathy: data from the Heart Muscle Disease Registry of Trieste. Clin Med Res 8(3–4):142–149. https://doi.org/10.3121/cmr.2010.908CrossRefPubMedPubMedCentral

81.

Aleksova A, Carriere C, Zecchin M et al (2014) New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 16(10):1450–1459. https://doi.org/10.1093/europace/euu016CrossRef

82.

Malhotra A, Dhutia H, Yeo T-J et al (2020) Accuracy of the 2017 international recommendations for clinicians who interpret adolescent athletes’ ECGs: a cohort study of 11 168 British white and black soccer players. Br J Sports Med 54(12):739–745. https://doi.org/10.1136/bjsports-2017-098528CrossRefPubMed

83.

Sharma S, Drezner JA, Baggish A et al (2018) International recommendations for electrocardiographic interpretation in athletes. Eur Heart J 39(16):1466–1480. https://doi.org/10.1093/eurheartj/ehw631CrossRefPubMed

84.

Puggia I, Merlo M, Barbati G et al (2016) Natural history of dilated cardiomyopathy in children. J Am Heart Assoc 5(7). https://doi.org/10.1161/JAHA.116.003450

85.

Losurdo P, Stolfo D, Merlo M et al (2016) Early arrhythmic events in idiopathic dilated cardiomyopathy. JACC Clin Electrophysiol 2(5):535–543. https://doi.org/10.1016/j.jacep.2016.05.002CrossRefPubMed

86.

Pinamonti B, Di Lenarda A, Sinagra G, Camerini F (1993) Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cardiol 22(3):808–815. https://doi.org/10.1016/0735-1097(93)90195-7CrossRefPubMed

87.

Rossi A, Dini FL, Faggiano P et al (2011) Independent prognostic value of functional mitral regurgitation in patients with heart failure. a quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97(20):1675–1680. https://doi.org/10.1136/hrt.2011.225789

88.

Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G (2011) Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 57(13):1468–1476. https://doi.org/10.1016/j.jacc.2010.11.030CrossRefPubMed

89.

Puwanant S, Priester TC, Mookadam F, Bruce CJ, Redfield MM, Chandrasekaran K (2009) Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr 10(6):733–737. https://doi.org/10.1093/ejechocard/jep052CrossRefPubMed

90.

Verdonschot JAJ, Merken JJ, Brunner-La Rocca H-P et al (2020) Value of speckle tracking–based deformation analysis in screening relatives of patients with asymptomatic dilated cardiomyopathy. JACC Cardiovasc Imaging 13(2):549–558. https://doi.org/10.1016/j.jcmg.2019.02.032CrossRefPubMed

91.

Romano S, Judd RM, Kim RJ et al (2018) Feature-tracking global longitudinal strain predicts death in a multicenter population of patients with ischemic and nonischemic dilated cardiomyopathy incremental to ejection fraction and late gadolinium enhancement. JACC Cardiovasc Imaging 11(10):1419–1429. https://doi.org/10.1016/j.jcmg.2017.10.024CrossRefPubMedPubMedCentral

92.

Norman M, Simpson M, Mogensen J et al (2005) Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 112(5):636–642. https://doi.org/10.1161/CIRCULATIONAHA.104.532234CrossRefPubMed

93.

Sepehrkhouy S, Gho JMIH, van Es R et al (2017) Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm 14(7):1024–1032. https://doi.org/10.1016/j.hrthm.2017.03.034CrossRefPubMed

94.

Millar LM, Fanton Z, Finocchiaro G et al (2020) Differentiation between athlete’s heart and dilated cardiomyopathy in athletic individuals. Heart 106(14):1059–1065. https://doi.org/10.1136/heartjnl-2019-316147CrossRefPubMed

95.

Le T-T, Bryant JA, Ang BWY et al (2020) The application of exercise stress cardiovascular magnetic resonance in patients with suspected dilated cardiomyopathy. J Cardiovasc Magn Reson 22(1):10. https://doi.org/10.1186/s12968-020-0598-4CrossRefPubMedPubMedCentral

96.

Pelliccia A, Corrado D, Bjørnstad HH et al (2006) Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil 13(6):876–885. https://doi.org/10.1097/01.hjr.0000238393.96975.32CrossRefPubMed

97.

Hey TM, Rasmussen TB, Madsen T et al (2020) Clinical and genetic investigations of 109 index patients with dilated cardiomyopathy and 445 of their relatives. Circ Heart Fail 13(10). https://doi.org/10.1161/CIRCHEARTFAILURE.119.006701

98.

Lee DS, Pencina MJ, Benjamin EJ et al (2006) Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 355(2):138–147. https://doi.org/10.1056/NEJMoa052948CrossRefPubMed

99.

Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet 17(5):405–424. https://doi.org/10.1038/gim.2015.30CrossRef

100.

Lahrouchi N, Raju H, Lodder EM et al (2017) Utility of post-mortem genetic testing in cases of sudden arrhythmic death syndrome. J Am Coll Cardiol 69(17):2134–2145. https://doi.org/10.1016/j.jacc.2017.02.046CrossRefPubMedPubMedCentral

101.

Al-Khatib SM, Stevenson WG, Ackerman MJ et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138(13). https://doi.org/10.1161/CIR.0000000000000549

102.

de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI et al (1997) Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 30(6):1500–1505. https://doi.org/10.1016/S0735-1097(97)00355-0CrossRefPubMed

103.

Gorgels A (2003) Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 24(13):1204–1209. https://doi.org/10.1016/S0195-668X(03)00191-X

104.

Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M (2014) Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 7(2):250–258. https://doi.org/10.1161/CIRCIMAGING.113.001144CrossRefPubMed

105.

Di Marco A, Anguera I, Schmitt M et al (2017) Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy. JACC Heart Fail 5(1):28–38. https://doi.org/10.1016/j.jchf.2016.09.017CrossRefPubMed

106.

Masci PG, Schuurman R, Andrea B et al (2013) Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging 6(5):790–799. https://doi.org/10.1161/CIRCIMAGING.113.000438CrossRefPubMed

107.

López-Ayala JM, Gómez-Milanés I, Sánchez Muñoz JJ et al (2014) Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. EP Eur 16(12):1838–1846. https://doi.org/10.1093/europace/euu128CrossRef

108.

Bhonsale A, Groeneweg JA, James CA et al (2015) Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 36(14):847–855. https://doi.org/10.1093/eurheartj/ehu509CrossRefPubMed

109.

Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D (2006) Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 354(2):209–210. https://doi.org/10.1056/NEJMc052632CrossRefPubMed

110.

Hodgkinson K, Connors S, Merner N et al (2013) The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43: natural history of a genetic subtype of ARVC. Clin Genet 83(4):321–331. https://doi.org/10.1111/j.1399-0004.2012.01919.x

111.

van Rijsingen IAW, van der Zwaag PA, Groeneweg JA et al (2014) Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 7(4):455–465. https://doi.org/10.1161/CIRCGENETICS.113.000374CrossRefPubMed

112.

Domínguez F, Cuenca S, Bilińska Z et al (2018) Dilated cardiomyopathy due to BLC2-sssociated athanogene 3 (BAG3) mutations. J Am Coll Cardiol 72(20):2471–2481. https://doi.org/10.1016/j.jacc.2018.08.2181CrossRefPubMedPubMedCentral

113.

Odgerel Z, Sarkozy A, Lee H-S et al (2010) Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscul Disord 20(7):438–442. https://doi.org/10.1016/j.nmd.2010.05.004CrossRefPubMedPubMedCentral

114.

Selcen D, Muntoni F, Burton BK et al (2008) Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann Neurol 65(1):83–89. https://doi.org/10.1002/ana.21553CrossRef

115.

Vorgerd M, van der Ven PFM, Bruchertseifer V et al (2005) A mutation in the dimerization domain of filamin C causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Genet 77(2):297–304. https://doi.org/10.1086/431959CrossRefPubMedPubMedCentral

116.

Merner ND, Hodgkinson KA, Haywood AFM et al (2008) Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 82(4):809–821. https://doi.org/10.1016/j.ajhg.2008.01.010CrossRefPubMedPubMedCentral

117.

Miles C, Finocchiaro G, Papadakis M et al (2019) Sudden death and left ventricular involvement in arrhythmogenic cardiomyopathy. Circulation 139(15):1786–1797. https://doi.org/10.1161/CIRCULATIONAHA.118.037230CrossRefPubMedPubMedCentral

118.

Gatzoulis KA, Tsiachris D, Arsenos P et al (2019) Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J 40(35):2940–2949. https://doi.org/10.1093/eurheartj/ehz260CrossRefPubMedPubMedCentral

119.

Gatzoulis KA, Dilaveris P, Arsenos P et al (2020) Arrhythmic risk stratification in nonischemic dilated cardiomyopathy: The ReCONSIDER study design - a two-step, multifactorial, electrophysiology-inclusive approach. Hell J Cardiol HJC Hell Kardiologike Epitheorese. Published Online 21 Apr 2020 https://doi.org/10.1016/j.hjc.2020.03.008

120.

Pelliccia A, Sharma S, Gati S et al (2020) 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. Published online 29 Aug 2020:ehaa605. https://doi.org/10.1093/eurheartj/ehaa605

121.

Bakalakos A, Ritsatos K, Anastasakis A (2018) Current perspectives on the diagnosis and management of dilated cardiomyopathy beyond heart failure: a Cardiomyopathy Clinic Doctor’s point of view. Hellenic J Cardiol 59(5):254–261. https://doi.org/10.1016/j.hjc.2018.05.008CrossRefPubMed

122.

Hershberger RE, Parks SB, Kushner JD et al (2008) Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci 1(1):21–26. https://doi.org/10.1111/j.1752-8062.2008.00017.xCrossRefPubMedPubMedCentral

123.

Laurent G, Saal S, Amarouch MY et al (2012) Multifocal ectopic Purkinje-related premature contractions. J Am Coll Cardiol 60(2):144–156. https://doi.org/10.1016/j.jacc.2012.02.052CrossRefPubMed

124.

McNair WP, Sinagra G, Taylor MRG et al (2011) SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol 57(21):2160–2168. https://doi.org/10.1016/j.jacc.2010.09.084CrossRefPubMed

125.

Mann SA, Castro ML, Ohanian M et al (2012) R222Q SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy. J Am Coll Cardiol 60(16):1566–1573. https://doi.org/10.1016/j.jacc.2012.05.050CrossRefPubMed

126.

Zakrzewska-Koperska J, Franaszczyk M, Bilińska Z et al (2018) Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case report. BMC Med Genet 19(1):94. https://doi.org/10.1186/s12881-018-0599-4CrossRefPubMedPubMedCentral

127.

Muchir A, Wu W, Choi JC et al (2012) Abnormal p38 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet 21(19):4325–4333. https://doi.org/10.1093/hmg/dds265CrossRefPubMedPubMedCentral

128.

Ware JS, Cook SA (2018) Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat Rev Cardiol 15(4):241–252. https://doi.org/10.1038/nrcardio.2017.190CrossRefPubMed

129.

Verdonschot JAJ, Hazebroek MR, Derks KWJ et al (2018) Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J 39(10):864–873. https://doi.org/10.1093/eurheartj/ehx808CrossRefPubMed

130.

Ma N, Zhang JZ, Itzhaki I et al (2018) Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent stem cells. Circulation 138(23):2666–2681. https://doi.org/10.1161/CIRCULATIONAHA.117.032273CrossRefPubMedPubMedCentral

131.

El Refaey M, Xu L, Gao Y et al (2017) In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice. Circ Res 121(8):923–929. https://doi.org/10.1161/CIRCRESAHA.117.310996CrossRefPubMedPubMedCentral

132.

van Mil A, Balk GM, Neef K et al (2018) Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential. Cardiovasc Res 114(14):1828–1842. https://doi.org/10.1093/cvr/cvy208CrossRefPubMedPubMedCentral

133.

Tse H-F, Ho JCY, Choi S-W et al (2013) Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. Hum Mol Genet 22(7):1395–1403. https://doi.org/10.1093/hmg/dds556CrossRefPubMed

134.

Wu H, Lee J, Vincent LG et al (2015) Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised β-adrenergic signaling in an iPSC model of dilated cardiomyopathy. Cell Stem Cell 17(1):89–100. https://doi.org/10.1016/j.stem.2015.04.020CrossRefPubMedPubMedCentral

135.

Sun N, Yazawa M, Liu J et al (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 4(130):130ra47. https://doi.org/10.1126/scitranslmed.3003552

136.

Karakikes I, Stillitano F, Nonnenmacher M et al (2015) Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 6:6955. https://doi.org/10.1038/ncomms7955CrossRefPubMed

137.

Wyles SP, Hrstka SC, Reyes S, Terzic A, Olson TM, Nelson TJ (2016) Pharmacological modulation of calcium homeostasis in familial dilated cardiomyopathy: an in vitro analysis from an RBM20 patient-derived iPSC Model. Clin Transl Sci 9(3):158–167. https://doi.org/10.1111/cts.12393CrossRefPubMedPubMedCentral

138.

Hinson JT, Chopra A, Nafissi N et al (2015) Heart Disease. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349(6251):982–986. https://doi.org/10.1126/science.aaa5458

139.

Judge LM, Perez-Bermejo JA, Truong A et al (2017) A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress. JCI Insight 2(14). https://doi.org/10.1172/jci.insight.94623

140.

Stillitano F, Turnbull IC, Karakikes I et al (2016) Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J 37(43):3282–3284. https://doi.org/10.1093/eurheartj/ehw307CrossRefPubMedPubMedCentral

141.

For the ClinGen Cardiovascular Clinical Domain Working Group, Kelly MA, Caleshu C et al (2018) Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel. Genet Med 20(3):351–359. https://doi.org/10.1038/gim.2017.218

142.

Manrai AK, Funke BH, Rehm HL et al (2016) Genetic misdiagnoses and the potential for health disparities. N Engl J Med 375(7):655–665. https://doi.org/10.1056/NEJMsa1507092CrossRefPubMedPubMedCentral

143.

Zecchin M, Merlo M, Pivetta A et al (2012) How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with “SCD-HeFT Criteria?” Am J Cardiol 109(5):729–735. https://doi.org/10.1016/j.amjcard.2011.10.033CrossRefPubMed

144.

Sinagra G, Merlo M, Pinamonti B (Ed.) (2019) Dilated cardiomyopathy: from genetics to clinical management. Springer International Publishing. https://doi.org/10.1007/978-3-030-13864-6

145.

Ruiz-Zamora I, Rodriguez-Capitan J, Guerrero-Molina A et al (2016) Incidence and prognosis implications of long term left ventricular reverse remodeling in patients with dilated cardiomyopathy. Int J Cardiol 203:1114–1121. https://doi.org/10.1016/j.ijcard.2015.11.099CrossRefPubMed

146.

Gulati A, Ismail TF, Jabbour A et al (2013) The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation 128(15):1623–1633. https://doi.org/10.1161/CIRCULATIONAHA.113.002518CrossRefPubMed

147.

Merlo M, Gobbo M, Stolfo D et al (2016) The prognostic impact of the evolution of RV function in idiopathic DCM. JACC Cardiovasc Imaging 9(9):1034–1042. https://doi.org/10.1016/j.jcmg.2016.01.027CrossRefPubMed

148.

Stolfo D, Tonet E, Barbati G et al (2015) Acute hemodynamic response to cardiac resynchronization in dilated cardiomyopathy: effect on late mitral regurgitation. Pacing Clin Electrophysiol PACE 38(11):1287–1296. https://doi.org/10.1111/pace.12731CrossRefPubMed

149.

Stolfo D, Merlo M, Pinamonti B et al (2015) Early improvement of functional mitral regurgitation in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 115(8):1137–1143. https://doi.org/10.1016/j.amjcard.2015.01.549CrossRefPubMed

150.

Verdonschot JAJ, Hazebroek MR, Wang P et al (2018) Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circ Heart Fail 11(11):e005220. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005220CrossRefPubMed

151.

Dal Ferro M, Stolfo D, Altinier A et al (2017) Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart Br Card Soc 103(21):1704–1710. https://doi.org/10.1136/heartjnl-2016-311017CrossRef

152.

Merlo M, Stolfo D, Anzini M et al (2015) Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long‐term follow‐up: does real healing exist? J Am Heart Assoc Cardiovasc Cerebrovasc Dis 4(1). https://doi.org/10.1161/JAHA.114.001504

153.

Fatkin D, Huttner IG, Kovacic JC, Seidman JG, Seidman CE (2019) Precision medicine in the management of dilated cardiomyopathy. J Am Coll Cardiol 74(23):2921–2938. https://doi.org/10.1016/j.jacc.2019.10.011CrossRefPubMed

154.

Hershberger RE, Givertz MM, Ho CY et al (2018) Genetic evaluation of cardiomyopathy—a Heart Failure Society of America Practice Guideline. J Card Fail 24(5):281–302. https://doi.org/10.1016/j.cardfail.2018.03.004CrossRefPubMed

155.

Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R (2018) Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Am Coll Cardiol 72(7):784–804. https://doi.org/10.1016/j.jacc.2018.05.065CrossRefPubMed

156.

Finocchiaro G, Merlo M, Sheikh N et al (2020) The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. Eur J Heart Fail 22(7):1097–1107. https://doi.org/10.1002/ejhf.1815CrossRefPubMed

157.

Gerull B, Gramlich M, Atherton J et al (2002) Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 30(2):201–204. https://doi.org/10.1038/ng815CrossRefPubMed

158.

Akhtar MM, Lorenzini M, Cicerchia M et al (2020) Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene. Circ Heart Fail 13(10). https://doi.org/10.1161/CIRCHEARTFAILURE.119.006832

159.

Tayal U, Newsome S, Buchan R et al (2017) Truncating variants in titin independently predict early arrhythmias in patients with dilated cardiomyopathy. J Am Coll Cardiol 69(19):2466–2468. https://doi.org/10.1016/j.jacc.2017.03.530CrossRefPubMedPubMedCentral

160.

Vasilescu C, Ojala TH, Brilhante V et al (2018) Genetic basis of severe childhood-onset cardiomyopathies. J Am Coll Cardiol 72(19):2324–2338. https://doi.org/10.1016/j.jacc.2018.08.2171CrossRefPubMed

161.

Frank D, Rangrez AY, Friedrich C et al (2019) Cardiac α-Actin ( ACTC1 ) gene mutation causes atrial-septal defects associated with late-onset dilated cardiomyopathy. Circ Genomic Precis Med 12(8). https://doi.org/10.1161/CIRCGEN.119.002491

162.

Vatta M, Mohapatra B, Jimenez S et al (2003) Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 42(11):2014–2027. https://doi.org/10.1016/j.jacc.2003.10.021CrossRefPubMed

163.

Bainbridge MN, Davis EE, Choi W-Y et al (2015) Loss of function mutations in NNT are associated with left ventricular noncompaction. Circ Cardiovasc Genet 8(4):544–552. https://doi.org/10.1161/CIRCGENETICS.115.001026CrossRefPubMedPubMedCentral

164.

Daehmlow S, Erdmann J, Knueppel T et al (2002) Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun 298(1):116–120. https://doi.org/10.1016/s0006-291x(02)02374-4CrossRefPubMed

165.

Carroll KJ, Makarewich CA, McAnally J et al (2016) A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci U S A 113(2):338–343. https://doi.org/10.1073/pnas.1523918113CrossRefPubMed

166.

Kamisago M, Sharma SD, DePalma SR et al (2000) Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343(23):1688–1696. https://doi.org/10.1056/NEJM200012073432304CrossRefPubMed

167.

Borkar M, Bijarnia-Mahay S, Kohli S et al (2015) Identification of a novel TAZ gene mutation in a family with X-linked dilated cardiomyopathy Barth syndrome. J Inborn Errors Metab Screen 3:232640981456713. https://doi.org/10.1177/2326409814567131CrossRef

168.

Mogensen J, Murphy RT, Shaw T et al (2004) Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 44(10):2033–2040. https://doi.org/10.1016/j.jacc.2004.08.027CrossRefPubMed

169.

Carballo S, Robinson P, Otway R et al (2009) Identification and functional characterization of cardiac troponin I as a novel disease gene in autosomal dominant dilated cardiomyopathy. Circ Res 105(4):375–382. https://doi.org/10.1161/CIRCRESAHA.109.196055CrossRefPubMed

170.

Olson TM, Kishimoto NY, Whitby FG, Michels VV (2001) Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 33(4):723–732. https://doi.org/10.1006/jmcc.2000.1339CrossRefPubMed

171.

Fatkin D, MacRae C, Sasaki T et al (1999) Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341(23):1715–1724. https://doi.org/10.1056/NEJM199912023412302CrossRefPubMed

172.

Domínguez F, Cuenca S, Bilińska Z et al (2018) Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. J Am Coll Cardiol 72(20):2471–2481. https://doi.org/10.1016/j.jacc.2018.08.2181CrossRefPubMedPubMedCentral

173.

Deo RC, Musso G, Tasan M et al (2014) Prioritizing causal disease genes using unbiased genomic features. Genome Biol 15(12):534. https://doi.org/10.1186/s13059-014-0534-8CrossRefPubMed

174.

Milting H, Klauke B, Christensen AH et al (2015) The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. Eur Heart J 36(14):872–881. https://doi.org/10.1093/eurheartj/ehu077

175.

Haghighi K, Kolokathis F, Pater L et al (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111(6):869–876. https://doi.org/10.1172/JCI17892CrossRefPubMedPubMedCentral

176.

Garcia-Pavia P, Syrris P, Salas C et al (2011) Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart Br Card Soc 97(21):1744–1752. https://doi.org/10.1136/hrt.2011.227967CrossRef

177.

Olson TM, Michels VV, Ballew JD et al (2005) Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 293(4):447–454. https://doi.org/10.1001/jama.293.4.447CrossRefPubMedPubMedCentral

178.

Li D, Tapscoft T, Gonzalez O et al (1999) Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100(5):461–464. https://doi.org/10.1161/01.cir.100.5.461CrossRefPubMed

179.

van Tintelen JP, Van Gelder IC, Asimaki A et al (2009) Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm 6(11):1574–1583. https://doi.org/10.1016/j.hrthm.2009.07.041CrossRefPubMed

180.

Ben Yaou R, Gerard M, Chami K et al (2014) G.P.142. Neuromuscul Disord 24(9–10):843–844. https://doi.org/10.1016/j.nmd.2014.06.172

Titel: Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments
verfasst von: Nicoletta Orphanou
Efstathios Papatheodorou
Aris Anastasakis
Publikationsdatum: 14.07.2021
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 4/2022
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-021-10139-0

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments

Abstract

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Minimally invasive versus conventional continuous-flow left ventricular assist device implantation for heart failure: a meta-analysis

Efficacy of motivational interviewing on enhancing self-care behaviors among patients with chronic heart failure: a systematic review and meta-analysis of randomized controlled trials

Heart–lung interactions in COVID-19: prognostic impact and usefulness of bedside echocardiography for monitoring of the right ventricle involvement

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases

The non-invasive assessment of myocardial work by pressure-strain analysis: clinical applications

Risk stratification in cardiogenic shock: a focus on the available evidence

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie